OREANDA-NEWS. B.R.A.I.N. Biotechnology Research And Information Network AG (ISIN: DE0005203947) has been listed in the Prime Standard of the Frankfurt Stock Exchange since 9 February 2016. About 4.0 million shares were placed in the IPO. The total issue volume was approximately €31.5 million. The initial listing price was €9.15; the issue price €9.00.

The first IPO in 2016 was supported by Oddo Seydler Bank AG, as a designated sponsor on Xetra and also as the specialist on the Börse Frankfurt venue.

According to the company, BRAIN is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. These innovative solutions and products are applied in the chemistry, cosmetics and food industries. BRAIN’s business model is based on two pillars – “BioScience” and “BioIndustrial”. The first pillar, “BioScience”, comprises (often exclusively) collaborative business with industrial partners. The second pillar “BioIndustrial” focuses on the development and commercialisation of BRAIN’s own products and active product components.